Evaluation of a prehospital chest pain protocol.
OBJECTIVE
To evaluate the diagnostic accuracy and outcomes for patients treated by use of a prehospital chest pain protocol (CPP).


METHODS
Consecutive case series for 1 year (1993) of prehospital nontrauma advanced life support (ALS) cases including hospital outcomes.


METHODS
Nonurban two-tiered emergency medical services system.


METHODS
Patients treated under the prehospital CPP or with hospital diagnoses of ischemic heart disease (IHD; ICD-9 between 410 and 414). Patients with cardiac arrest or dysrhythmias were excluded.


METHODS
Patients were given, by standing orders, ECG monitoring, i.v. access, and sublingual nitroglycerin. Further therapy was guided by on-line medical direction.


RESULTS
Of 3,122 ALS nontrauma patients, 620 (20%) were treated with the CPP. All patients underwent ECG monitoring, i.v. access was started in 83%, and 61% received nitroglycerin. Only 55% of patients completed the entire CPP; patients who failed to complete the CPP had the same prevalence of IHD as those who completed it. When compared with hospital diagnosis of IHD, the CPP had a sensitivity of 69% (95% confidence interval [CI], 64% to 74%), a specificity of 87% (95% CI, 86% to 88%), and a positive predictive value of 42%. The positive likelihood ratio of CPP for IHD was 5.31, and the negative likelihood ratio was .36. The hospital mortality rate for all patients was 2.2%; for those with IHD, it was 1.6%.


CONCLUSIONS
This prehospital ALS CPP had good diagnostic accuracy, but only half of patients completed it, and the hospital mortality rate was low. These data challenge the efficacy of the CPP.
D000787:Angina Pectoris / Q000175:diagnosis* / Q000188:drug therapy; D002637:Chest Pain / Q000188:drug therapy / Q000209:etiology*; D002985:Clinical Protocols / Q000592:standards*; D004562:Electrocardiography; D004632:Emergency Medical Services / Q000592:standards*; D017052:Hospital Mortality; D006801:Humans; D005996:Nitroglycerin / Q000627:therapeutic use; D010414:Pennsylvania; D015995:Prevalence; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D005996:Nitroglycerin